Phase IIb Multi-center, Double-blind, Randomized, Parallel Group, Placebo Controlled Clinical Trial for the Assessment of Lipid Trends and Safety of RVX000222 in Statin Treated Subjects With Low Baseline HDL-C Concentrations.

Trial Profile

Phase IIb Multi-center, Double-blind, Randomized, Parallel Group, Placebo Controlled Clinical Trial for the Assessment of Lipid Trends and Safety of RVX000222 in Statin Treated Subjects With Low Baseline HDL-C Concentrations.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 May 2017

At a glance

  • Drugs Apabetalone (Primary)
  • Indications Coronary artery disease; Low HDL cholesterol
  • Focus Therapeutic Use
  • Acronyms SUSTAIN
  • Sponsors Resverlogix Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 31 May 2017 According to a Resverlogix Corporation media release, results from the post-hoc analysis of SUSTAIN and ASSURE trials will be presented at the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress 2017.
    • 09 Nov 2015 Results from the post-hoc analysis of SUSTAIN and ASSURE trials comparing data between patients with and without MACE were presented at the American Society of Nephrology (ASN) Kidney Week conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top